Neven A, Dumont G J H
Tijdschr Psychiatr. 2023;65(1):29-34.
Patients with opiate use disorder may be treated medicamentally with methadone and sublingual buprenorphine. However, also two forms of subcutaneous buprenorphine that can be administered weekly or monthly are available.
To describe the effectiveness and the side effects of the buprenorphine depot.
Embase was searched and cross-references were sought in the included studies and previous reviews.
Nine articles were included. One randomized study (n = 428) compared buprenorphine depot to the sublingual form, with the depot being more effective after 12-24 weeks. The other randomized study (n = 504) compared the depot with placebo. The depot was found to be effective. In two comparative non-blinded studies, no significant difference in abstinence was reported between the depot and sublingual administration. Medium-term effectiveness (16-52 weeks) was confirmed in five follow-up studies, in which the depot preparation proved both effective and well tolerated.
The buprenorphine depot is described as promising in the international literature. However, there are still several uncertainties that make its prescription should be done with great caution.
患有阿片类药物使用障碍的患者可以使用美沙酮和舌下含服丁丙诺啡进行药物治疗。然而,也有两种可每周或每月给药一次的皮下注射丁丙诺啡剂型。
描述丁丙诺啡长效注射剂的有效性和副作用。
检索了Embase数据库,并在纳入研究和既往综述中查找交叉参考文献。
纳入9篇文章。一项随机研究(n = 428)比较了丁丙诺啡长效注射剂与舌下含服剂型,结果显示长效注射剂在12 - 24周后更有效。另一项随机研究(n = 504)比较了长效注射剂与安慰剂,发现长效注射剂有效。在两项非盲对照研究中,未报告长效注射剂与舌下给药在戒断方面存在显著差异。五项随访研究证实了中期有效性(16 - 52周),其中长效注射剂制剂被证明既有效又耐受性良好。
国际文献中称丁丙诺啡长效注射剂前景良好。然而,仍存在一些不确定性,这使得其处方开具应极为谨慎。